Read Article

Supporting international business matching, LSMIP propritizes "Speed" and "Accuracy" in out service.
Please be noted that contents are in English/Japanese, translated on a request basis from authors/members.
国際間のビジネス・マッチングを促進するため、LSMIPでは情報発信の迅速性・正確性を重視しております。
コンテンツは各言語(英語、日本語)でお読みいただけますが、必要に応じて翻訳する場合があります。

Overview

0

The Hope for Oral Delivery of Biologics for DDE business

White Papers of Drug Delivery – Part 1/3
Christopher A. Rhodes (Ph.D), President & CEO of DDE Labs, Inc.
06 September 2019
  • Target market
    USA
  • Business category
    Pharmaceutical, Biopharmaceutical, Regerative medicine
  • Business function
  • Keyword
  • Author
    "Chris Rhodes" of "Drug Delivery Experts, LLC."
  • Availability
    Membership

Detail

White Papers of Drug Delivery  – Part 1/3
Christopher A. Rhodes (Ph.D), President & CEO of DDE Labs, Inc.
06 September 2019

  Drug Delivery Technologies have been evolving with the development of pharmaceutics and biologics. 
  With these 3 articles, Dr. Christopher Rhodes, CEO of DDE Labs,  describes the development and the frontline of Drug Delivery.
This is Part 1 of a Series of 3 segments.

(Table of content)
Part 1
    - The Hope for Oral Delivery of Biologics

Part 2
    - Renewed Interest in Long-Acting Injectable and Implantable Drug Products
Part 3
    - The Challenges of Complex Generics

Keywords for the article: Drug Delivery, Oral Delivery, Injectable, Implantable, Long-acting systems,


The Hope for Oral Delivery of Biologics

  The hope has been that biologics injectable products could be converted to oral therapies in the form of a tablet or capsule.  This would greatly expand the utilization by patients and physicians, and in turn the market potential for these already valuable injectable products. In addition, from a product support perspective, patients know what to do with an oral tablet or capsule and require no training.  On the other hand, injectable systems require training prior to use and ongoing technical support, which can be quite significant costs for commercial pharmaceutical organizations.
 
(Continued..)

Comments (Require approval)

What information are you looking for in articles?
Let us help you to find out the articles for your business requirements!
Like many other companies, we use cookies and other technologies, some of which are essential to make our website work. By clicking Accept or continuing to use our site, you agree to use these cookies and other technologies. To learn more, check out our privacy policy.
Accept